𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Heterogeneity of bromodeoxyuridine sensitivity of cultured cells from melanoma metastases

✍ Scribed by Martin Poot; Karl-Heinz Hiller; Simone Heimpel; Armin Schuster; Julia Köhler; Holger Hoehn


Book ID
102816030
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
529 KB
Volume
21
Category
Article
ISSN
0196-4763

No coin nor oath required. For personal study only.

✦ Synopsis


Continuously growing cell cultures, testing positive for tyrosinase activity, were derived from two brain and three lymph-node metastases of five patients with malignant melanoma. These cell cultures were analyzed regarding their proliferation fate with continuous bromodeoxyuridine (BrdUrd) labeling followed by bivariate Hoechst 33258/ethidium bromide flow cytometry. Melanoma cell cultures are more sensitive toward BrdUrd in comparison to human diploid fibroblast cultures: 50% growth inhibition at 360 f 130 p M BrdUrd (range: 130-520; n = 11) vs. 650 f 50 pM BrdUrd (n = 3) for fibroblasts. Moreover, BrdUrd sensitivity in melanoma cells is oxygen dependent: 50% growth inhi- bition at 200 2 55 pM (range: 65-400 FM) for 20% oxygen vs. 360 f 130 p M BrdUrd for 5% oxygen. The cell cycle kinetic mechanism of BrdUrd-induced growth inhibition is accumulation of cells in the G2 phase. Cultures from a single metastasis showed up to a 3-fold variation in BrdUrd sensitivity. I n one of the brain metastases two populations of different ploidy level (pseudotriploid vs. pseudotetraploid) and BrdUrd sensitivity could be resolved. Thus, continuous BrdUrd labeling followed by bivariate Hoechst 3325Wethidium bromide flow cytometry is a powerful tool to detect heterogeneity in proliferative capacity and drug sensitivity of cell populations within one tumor biopsy.


📜 SIMILAR VOLUMES


Serological responses of melanoma patien
✍ Philip O. Livingston; Hideo Takeyama; Marilyn S. Pollack; Alan N. Houghton; Anth 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 French ⚖ 769 KB

## Abstract Twenty melanoma patients were immunized with a whole‐cell vaccine prepared from irradiated cells of the melanoma cell line SK‐MEL‐13. This line, derived from the melanoma of patient AH, expresses a differentiation antigen (initially defined by autologous antibody) which is restricted to